Microbiology Nuts & Bolts
  • Home
  • Basic Concepts
    • What is infection?
    • Normal flora
    • Diagnosing infection
  • Microbiology
    • Basic bacterial identification
    • Interpreting bacteriology results
    • Interpreting serology results
  • Infection Control
    • What is infection control?
    • Universal precautions
    • MRSA
    • Clostridium difficile
  • Clinical Scenarios
    • Respiratory infections
    • Urinary infections
    • GI infections >
      • D&V
      • CDAD
    • CNS infections
    • Skin & bone infections
    • Sepsis
  • Antibiotics
    • Antimicrobial Stewardship
    • How antibiotics work
    • How to choose an antibiotic?
    • Reviewing antibiotics
    • Antibiotic resistance
    • Testing antibiotic resistance
    • Penicillin allergy
    • Theraputic Drug Monitoring
  • Guidelines
  • Lectures & Lecture Notes
    • Medical Students
    • Curriculum for the Foundation Program
    • Foundation Year 1
    • Foundation Year 2
    • Other Lectures
  • The Bug Blog
  • Buy the book...
  • NEW Edition Updates
  • Peer Reviews
  • Our Facebook page
  • Want to know more?
  • Contact

PVL positive Staphylococcus aureus

19/5/2014

 
I have been asked many times over the last few years about
prophylactic antibiotics for patients with recurrent skin and soft tissue infections such as abscesses, boils, furuncles and carbuncles caused by Staphylococcus aureus. These patients have often been referred to an immunologist for investigation of underlying immunodeficiency and had numerous investigations but nothing wrong has ever been identified.
Usually in these situations the problem lies with the bacterium and not the patient. These bacteria are perfectly adapted at causing these types of infections and do so on a regular basis. The most common reason for this is the production of the toxin Panton-Valentine Leukocidin (PVL). Of the 30% of the population who have Staphylococcus aureus as part of their normal flora, approximately 2% have bacteria that can produce PVL toxin. PVL positive Staphylococcus aureus can be either MRSA or MSSA. It is
difficult to predict which will produce PVL toxin except on
the basis of a clinical history of recurrent skin and soft tissue
infections.
Picture
The PVL toxin is a defence mechanism used by the bacteria against the hosts’ immune system to break down white blood cells and increase the virulence of the bacterium. PVL positive Staphylococcus aureus often cause recurrent and severe skin and soft tissue infections, but occasionally they
cause more severe infections such as necrotising pneumonia, which has a 75% mortality rate.

Unfortunately PVL positive Staphylococcus aureus is very good at spreading around small groups with close contact such as schools, nurseries, nursing care homes, sporting teams and military barracks. This can lead to “recurrent infections” but in fact the individual reacquires the bacterium from someone else in the group even after having been successfully treated. The key to managing these situations is to try to eliminate the bacterium from the entire group, especially those that are carriers but are not symptomatic. Start by screening the entire group with nose swabs to detect carriage and then offer them all suppression therapy, the same regime used for Methicillin-resistant Staphylococcus aureus, see below. Then rescreen the entire group within a week and retreat if any are still positive.

Suppression Therapy
All cases



PLUS For adults
Mupirocin 2% nasal ointment (Bactroban) applied to inside of the nose 3 times per day for 5 days

4% Chlorhexidine body and hair wash 1 time per day for 5 days
Additionally during the period of suppression therapy specifically treat any group member with active skin
and soft tissue infections with Clindamycin OR Linezolid. These antibiotics have the ability to switch off toxin production and are usually enough to break the cycle of cross transmission.

The original patient can be reassured that there is nothing wrong with their immune system and that it is in fact the bacteria itself that is the problem. Managing this problem proactively protects the patient from the bacterium and also any harm caused as a result of unnecessary antibiotic prophylaxis. It takes time and effort but the benefits to the patient are worthwhile. As doctors we must be wary of using antibiotic prophylaxis as bacteria are far better at evolution than us. By giving prophylactic antibiotics (especially long courses or low doses) selective pressure is applied to the bacterium, it just evolves to survive the onslaught, develops resistance and becomes an alternative larger problem.
Elizabeth
1/7/2014 07:17:06 am

As a healthcare worker who has been sick for 8 months with PVL (as it recurred) what really are the chances of erradication? Being misdiagnosed and only diagnosed some 6 months later with horrendous continuing health problems that disappeared whilst full treatment took place only to reoccur within weeks. The more I read of the subject the more I think is unknown. So can the PVL be eradicated or is it suppressed?


Comments are closed.

    RSS Feed

    Blog Author:

    David Garner
    Consultant Microbiologist
    Surrey, UK

    Please DO NOT advertise products and conferences on our website or blog

    Categories

    All
    Antibiotic Resistance
    Antibiotics
    Basic Concepts
    Clinical Scenarios
    Guidelines
    Infection Control
    In The News
    Microbiology

    Archives

    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    October 2013
    September 2013
    August 2013
    July 2013

    Categories

    All
    Antibiotic Resistance
    Antibiotics
    Basic Concepts
    Clinical Scenarios
    Guidelines
    Infection Control
    In The News
    Microbiology

    RSS Feed

Powered by Create your own unique website with customizable templates.